Generic drugs saved people trillions. Could biosimilars do the same? Biologics like Ozempic make up 5% of prescriptions but more than half of drug spending. A new study found different approval rules may be slowing access to lower-cost alternatives. https://ow.ly/215150Z9ekH
UCSF research shows that international rules for biosimilars, mimics of biologic drugs like Ozempic and insulin, need to improve and match each another to encourage biosimilar development, testing, and approval. This would dramatically improve drug affordability just like generics has done.
